Quarterly report pursuant to Section 13 or 15(d)

NOTES PAYABLE (Details 1)

v3.21.2
NOTES PAYABLE (Details 1)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2021
USD ($)
Equity_Instrument
$ / shares
Dec. 31, 2020
USD ($)
Equity_Instrument
$ / shares
Feb. 21, 2020
Debt Instrument [Line Items]      
Interest rate     10.00%
Principal Outstanding $ 22,809 $ 15,294  
Unamortized Discount 4,732 1,720  
Carrying Amount $ 18,077 $ 13,574  
Underlying Shares Notes | Equity_Instrument 10,122,974 3,946,723  
Convertible notes payable, Non-current $ 12,908 $ 3,150  
2021 Convertible Notes Payable [Member]      
Debt Instrument [Line Items]      
Interest rate 2.00%    
Term of Notes 3 years    
Conversion Price | $ / shares [1] $ 1.48    
Principal Outstanding $ 14,490    
Unamortized Discount 4,732    
Carrying Amount $ 9,758    
Underlying Shares Notes | Equity_Instrument 9,806,305    
Convertible Notes Payable [Member]      
Debt Instrument [Line Items]      
Principal Outstanding $ 17,640 3,150  
Unamortized Discount 4,732    
Carrying Amount $ 12,908 $ 3,150  
Underlying Shares Notes | Equity_Instrument 10,122,974 316,723  
Principal Outstanding, Non Current $ 17,640    
Unamortized Discount, Non Current 4,732    
Convertible notes payable, Non-current $ 12,908    
Underlying Shares Notes, Non Current | Equity_Instrument 10,122,974    
Principal Outstanding, Current   $ 3,150  
Convertible notes payable, Current   $ 3,150  
Underlying Shares Notes, Current | Equity_Instrument   316,723  
2020 Convertible Notes Payable [Member]      
Debt Instrument [Line Items]      
Interest rate 12.00% 12.00%  
Term of Notes 3 years 3 years  
Conversion Price | $ / shares [2] $ 10.00 $ 10.00  
Principal Outstanding $ 3,150 $ 3,150  
Carrying Amount $ 3,150 $ 3,150  
Underlying Shares Notes | Equity_Instrument 316,669 316,723  
[1]

The notes are convertible into Emmaus Life Sciences, Inc. shares.

[2] The notes are convertible into EMI Holding, Inc. shares.